UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Convictions et croyances : que protège la liberté de conscience ?

Studies in religion, 2019-09, Vol.48 (3), p.361-381

Guichard, Sylvie

2019

Volltextzugriff (PDF)

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2508-2518

2015

Volltextzugriff (PDF)

Discovery of 4‑{4-[(3R)‑3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}‑1H‑indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

Journal of medicinal chemistry, 2013-03, Vol.56 (5), p.2125-2138

2013

Volltextzugriff (PDF)

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

Biochemical journal, 2013-06, Vol.452 (3), p.499-508

2013

Volltextzugriff (PDF)

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

Breast cancer research : BCR, 2014-01, Vol.16 (1), p.R12-R12, Article R12

2014

Volltextzugriff (PDF)

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Neuro-oncology (Charlottesville, Va.), 2023-01, Vol.25 (1), p.146-156

2023

Volltextzugriff (PDF)

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

Journal of cell science, 2014-02, Vol.127 (Pt 4), p.788

2014

Volltextzugriff (PDF)

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

Cancer discovery, 2011-08, Vol.1 (3), p.248-259

2011

Volltextzugriff (PDF)

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

Autophagy, 2010-05, Vol.6 (4), p.553-554

2010

Volltextzugriff (PDF)

The construction of history and nationalism in India: Textbooks, controversies and politics

Guichard, Sylvie

2010

Volltextzugriff (PDF)

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (7), p.1804-1813

2012

Volltextzugriff (PDF)

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival

Clinical cancer research, 2019-03, Vol.25 (5), p.1574-1587

2019

Volltextzugriff (PDF)

The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Clinical cancer research, 2020-07, Vol.26 (14), p.3751-3759

2020

Volltextzugriff (PDF)

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2489-2500

2014

Volltextzugriff (PDF)

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

Targeted oncology, 2023-03, Vol.18 (2), p.269-285

2023

Volltextzugriff (PDF)

Le Fichier parisien de Montherlant : déambulation urbaine et exploration intérieure

Babel (Mont-de-Marsan), 2014-06, Vol.27, p.87-114

Guichard, Sylvie

2014

Volltextzugriff (PDF)

A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055

British journal of pharmacology, 2017-08, Vol.174 (16), p.2652-2661

2017

Volltextzugriff (PDF)

mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment

Cancer research (Chicago, Ill.), 2011-06, Vol.71 (12), p.4074-4084

2011

Volltextzugriff (PDF)

Controlling Ligand Substitution Reactions of Organometallic Complexes: Tuning Cancer Cell Cytotoxicity

Proceedings of the National Academy of Sciences - PNAS, 2005-12, Vol.102 (51), p.18269-18274

2005

Volltextzugriff (PDF)

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055

Biochemical Society transactions, 2011-04, Vol.39 (2), p.456-459

2011

Volltextzugriff (PDF)

Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005-11, Vol.826 (1), p.232-237

2005

Volltextzugriff (PDF)

Structure−Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents

Journal of medicinal chemistry, 2010-04, Vol.53 (7), p.2927-2941

2010

Volltextzugriff (PDF)

Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008-02, Vol.863 (1), p.19-25

2008

Volltextzugriff (PDF)

1 – 25 von 283

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(241)
Mit Volltextzugriff
(258)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(116)
Life Sciences & Biomedicine
(104)
Humans
(78)
Life Sciences
(41)
Animals
(40)
Biological And Medical Sciences
(38)
Oncology
(35)
Female
(29)
Medical Sciences
(28)
Mice
(27)
Cell Line, Tumor
(22)
Pharmacology & Pharmacy
(20)
Pharmacology. Drug Treatments
(19)
Biochemistry & Molecular Biology
(17)
Antineoplastic Agents
(16)
Physical Sciences
(15)
Tor Serine-Threonine Kinases - Antagonists & Inhibitors
(14)
Fundamental And Applied Biological Sciences. Psychology
(13)
Geography
(13)
Humanities And Social Sciences
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Convictions et croyances : que protège la liberté de conscience ?

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Discovery of 4‑{4-[(3R)‑3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}‑1H‑indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

The construction of history and nationalism in India: Textbooks, controversies and politics

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival

The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

Le Fichier parisien de Montherlant : déambulation urbaine et exploration intérieure

A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055

mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase

Controlling Ligand Substitution Reactions of Organometallic Complexes: Tuning Cancer Cell Cytotoxicity

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055

Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies

Structure−Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents

Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies

Suchergebnisse filtern